Victory Capital Management Inc. bought a new position in shares of Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 458,340 shares of the company’s stock, valued at approximately $10,198,000. Victory Capital Management Inc. owned about 2.23% of Sienna Biopharmaceuticals as of its most recent SEC filing.
Sienna Biopharmaceuticals, Inc. (SNNA) opened at $18.76 on Wednesday. Sienna Biopharmaceuticals, Inc. has a 12-month low of $15.22 and a 12-month high of $29.25.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last posted its quarterly earnings data on Thursday, September 7th. The company reported ($6.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($5.82). analysts predict that Sienna Biopharmaceuticals, Inc. will post -2.1 EPS for the current fiscal year.
Several research analysts recently issued reports on the company. J P Morgan Chase & Co assumed coverage on Sienna Biopharmaceuticals in a research report on Monday, August 21st. They set an “overweight” rating and a $28.00 target price for the company. Cowen and Company assumed coverage on Sienna Biopharmaceuticals in a research report on Monday, August 21st. They set an “outperform” rating and a $50.00 target price for the company. Finally, BMO Capital Markets assumed coverage on Sienna Biopharmaceuticals in a research report on Monday, August 21st. They set an “outperform” rating and a $30.00 target price for the company.
In other Sienna Biopharmaceuticals news, Director Dennis M. Fenton acquired 1,250 shares of the stock in a transaction dated Monday, September 18th. The stock was purchased at an average cost of $22.96 per share, with a total value of $28,700.00. Following the transaction, the director now owns 1,250 shares in the company, valued at approximately $28,700. The acquisition was disclosed in a filing with the SEC, which is available at this link.
Sienna Biopharmaceuticals Profile
Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.
Receive News & Ratings for Sienna Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.